iifl-logo

Gaudium IVF and Women Health Ltd Management Discussions

Add as a Preferred Source on Google
96.91
(-6.92%)
Apr 17, 2026|05:30:00 AM

Gaudium IVF and Women Health Ltd Share Price Management Discussions

OPERATION

The following discussion of our financial condition and results of operations is based on, and should be read in
conjunction with, our Restated Consolidated Financial Statements (including the schedules, notes and significant
accounting policies thereto), included in the section titled "Restated Consolidated Financial Statements" beginning on
page 214.

Our Restated Consolidated Financial Statements have been derived from our audited financial statements and restated
in accordance with the SEBI ICDR Regulations and the ICAI Guidance Note. Our financial statements are prepared
in accordance with IND AS, notified under the Companies (Indian Accounting Standards) Rules, 2015, and read with
Section 133 of the Companies Act, 2013 to the extent applicable. IND AS differs in certain material respects from
IFRS and U.S. GAAP and other accounting principles with which prospective investors may be familiar. Accordingly,
the degree to which the financial statements prepared in accordance with IND AS included in this Draft Red Herring
Prospectus will provide meaningful information is entirely dependent on the readers level of familiarity with IND AS
accounting policies. We have not attempted to quantify the impact of IFRS or U.S. GAAP on the financial information
included in this Draft Red Herring Prospectus, nor do we provide a reconciliation of our financial information to IFRS
or U.S. GAAP. Any reliance by persons not familiar with IND AS accounting policies on the financial disclosures
presented in this Draft Red Herring Prospectus should accordingly be limited.

Unless otherwise indicated or the context requires otherwise, the financial information for Fiscal 2025, Fiscals 2024
and 2023 included herein have been derived from our restated consolidated balance sheets of March 31, 2025, March
31, 2024, March 31, 2023 and restated consolidated statements of profit and loss, cash flows and changes in equity
for the fiscal years ended March 31, 2025, March 31, 2024 and March 31, 2023 of the Company, together with the
statement of significant accounting policies, and other explanatory information thereon.

Unless stated otherwise, industry and market data used in this Draft Red Herring Prospectus has been obtained or
derived from the report titled "IVF and Fertility Services Industry Report " dated September 25, 2025 prepared by
Infomerics Analytics and Research Private Limited (the "Infomerics Research") and publicly available information
as well as other industry publications and sources. The Report has been exclusively commissioned at the request of
our Company and paid for by our Company for the purposes of this Issue and is available on the website of the
Company at www.gaudiumivfcentre.com .

Our fiscal year ends on March 31 of each year, and references to a particular fiscal period are to the 12 months ended
March 31 of that year. All references to a year are to that Fiscal Year, unless otherwise noted.

Some of the information contained in this section, including information with respect to our strategies, contain
forward-looking statements that involve risks and uncertainties. You should read the section titled "Forward Looking
Statements" beginning on page 21 for a discussion of the risks and uncertainties related to those statements and also
the section titled "Risk Factors" and "Our Business" beginning on pages 32 and 156, respectively, for a discussion of
certain factors that may affect our business, results of operations and financial condition. The actual results of the
Company may differ materially from those expressed in or implied by these forward-looking statements.

Unless otherwise stated, references to "the Company", "our Company", "we", "us", and "our" are to Gaudium IVF
and Women Health Limited.

Business Overview

Incorporated in the year 2015, our company is engaged in IVF (In vitro fertilization) treatment in India and has grown
into several states with Hub and spoke model over the years. Gaudium IVF is founded by our Promoter Dr. Manika
Khanna, a specialist with advanced training in gynecological endoscopic surgery from Kiel, Germany, and Melbourne
IVF Gujarat Private Limited. Having a PAN-India presence, the company operates 30+ locations, which comprises of
7 hubs (centers) and 28 spokes (company has entered into a strategic alliance with Spokes i.e Infertility Expert) to
achieve the mutual goal of spreading awareness about ART and IVF treatment). Our Main centers (Hubs) are located
in major cities of which 2 centers are located in Delhi (Janakpuri & Kailash Colony), 1 center in Maharashtra (Mumbai

-Khar West), 1 center in Punjab (Ludhiana), 1 center in Jammu & Kashmir (Srinagar), 1 center in Bihar (Patna) and
1 center in Karnataka (Bangalore), to cater potential locations across India.

Parenthood is a joyful journey, especially for mothers who experiences motherhood. We understand the challenges
couples face in building a family due to infertility, medical issues, or lifestyle factors. Our mission is to help make
their dream of parenthood come true through personalized fertility treatments. From the first consultation to a
successful pregnancy, we provide expert care, support, and a close partnership with our patients, ensuring a hopeful
and joyful future.

For further details, kindly refer "Our Business " on page 156
Key Performance Indicator

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Revenue from Operations

7,072.40 4,789.01 4,423.69

Total Revenue 1

7,095.84 4,815.31 4,426.02

EBITDA

2,862.59 1,927.47 2,006.55

EBIT

2,681.34 1,737.91 1,865.48

EBT

2,542.25 1,663.16 1,831.24

PAT

1,912.74 1,031.69 1,352.54

EBITDA Margin 2

40.48% 40.25% 45.36%

EBIT Margin 3

37.79% 36.29% 42.17%

EBT Margin 4

35.83% 34.54% 41.37%

PAT Margin 5

26.96% 21.43% 30.56%

RoE 6

41.31% 38.23% 59.51%

RoCE 7

39.70% 38.74% 54.40%

Note:

1 Total Revenue( Revenue from operations plus other Income)

2 EBITDA Margin is calculated as EBITDA divided by Revenue from Operation

3 EBIT Margin is calculated as EBIT divided by Revenue from operation
4? EBTMargin is calculated as EBT divided by Total Revenue

5? PAT Margin is calculated as PAT divided by Total Revenue
6 RoE (Return on Equity) is calculated as PAT divided by Equity (Net worth)

77 RoCE (Return on Capital Employed) is calculated as EBIT divided by Capital Employed (Net worth +

Borrowings + Lease Liabilities + Deferred Tax Liabilities)

Significant Factors Affecting our Result of Operations

The significant accounting policies applied by the Company in the preparation of its financial statements are listed
below. Such accounting policies have been applied consistently to all the periods presented in these financial
statements, unless otherwise indicated.

Presentation of Financial Information

The Restated Consolidated Financial Information of Gaudium IVF and Women Health Limited and its subsidiaries,
comprising the Restated Consolidated Statement of Assets and Liabilities as at 31st March 2025, and year ended 31st
March 2024, and year ended 31st March 2023, the Restated Consolidated Statement of Profit and Loss (including
Other Comprehensive Income) for the year ended 31st March 2025 and year ended 31st March 2024 and year ended
31st March 2023, the Restated Consolidated Statement of Cash Flows for the year ended 31st March 2025 and the year
ended 31st March 2024 and year ended 31st March 2023, The Restated Consolidated Changes in Equity for the year
ended 31st March 2025 and the year ended 31st March 2024, and year ended 31st March 2023 and the summary
statement of material accounting policies, and other explanatory information (collectively, the "Restated Consolidated
Financial Information"), as approved by the Board of Directors of the Company at their meeting held on 10th
September 2025 for the purpose of inclusion in the Draft Red Herring Prospectus ("DRHP")/Red Herring

Prospectus/Prospectus has been prepared by the Company in connection with its proposed initial public offer of equity
shares of the Company ("IPO") prepared in terms of the requirements of:

• Section 26 of Part I of Chapter III of the Companies Act, 2013, as amended ("the Act");

• The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations,
2018, as amended ("ICDR Regulations"); and

• The Guidance Note on Report in Company Prospectuses (Revised 2019) issued by the Institute of Chartered
Accountants of India (ICAI) as amended from time to time (the "Guidance Note").

These Restated Consolidated Financial Information have been compiled by the Management of the Company from:

• The Restated Consolidated Financial Statements as at and for the years ended 31st March 2025 and 31st March
2024 have been compiled by the Management from the audited consolidated financial statements of the
Company as at and for the year ended 31st March 2025 which include the comparative Ind AS consolidated
financial statements as at and for the year ended 31st March 2024 prepared in accordance with Indian
Accounting Standards (Ind AS) as prescribed under Section 133 of Companies Act, 2013 read with
Companies (Indian Accounting Standards) Rules 2015, subsequent amendments thereof and other relevant
provisions of the Act; and

• Special Purpose Ind AS Consolidated Financial Statements of the Group, for the year ended 31st March 2023,
which have been prepared in accordance with the Ind AS, as prescribed under Section 133 of the Act read
with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles
generally accepted in India and which have been approved by the Board of Directors at their meeting held
on 10th September 2025, after making Ind AS adjustments to the audited consolidated financial statements of
the Company as at and for the year ended 31st March, 2023, prepared in accordance with the Indian GAAP
which was approved by the Board of directors at their meeting held on 21st September 2023.

There are no qualifications in the Auditors Reports on the Audited Restated Consolidated Financial Statements of
the Group for the year ended 31st March 2025, and for the years ended 31st March 2024 and 31st March 2023 which
require any adjustments to the Restated Consolidated Financial Information and in the Companies (Auditors
Report) Order, 2020 issued by the Central Government of India in terms of sub-section (11) of section 143 of the
Act, which require any corrective adjustments in the Restated Consolidated Financial Information.

The explanation to Emphasis of Matter Paragraph provided by the Statutory Auditor and Compliance under Rule
11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended) which do not require any corrective
adjustments in the Restated Consolidated Financial Information have been disclosed in the Restated Consolidated
Financial Information. (Refer Note 39)

a) Historical Cost Convention

The Restated Consolidated Financial Information have been prepared on a historical cost basis, except for the
following:

• Certain financial assets and liabilities (including derivative instruments) and contingent consideration that is
measured at fair value or amortized cost;

• Defined benefit plans - plan assets measured at fair value;

b) Current / Non-Current Classification

Any asset or liability is satisfied as current if it satisfies any of the following conditions:

• Asset / Liability is expected to be realised / settled in the Groups normal operating cycle

• Asset is intended for sale or consumption

• Asset / Liability is held primarily for the purpose of trading

• Asset is a cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at
least twelve months after the reporting date

• In case of a Liability, the Group does not have an unconditional right to defer settlement of the liability for at
least twelve months after the reporting date

For the purpose of this classification, the Group has ascertained its normal operating cycle as twelve months, which
is based on the nature of business and time between acquisition of assets and inventories for processing and their
realisation in cash and cash equivalents.

c) Use of Material Accounting Estimates and Judgements

Estimates, assumptions concerning the future and judgements are made in the preparation of the financial
statements. They affect the application of the Groups accounting policies, reporting amounts of assets, liabilities,
income and expense and disclosures made. Although these estimates are based on managements best knowledge
of current events and actions, actual result may differ from those estimates.

The critical accounting estimates and assumptions used and areas involving a high degree of judgements are
described below:

3.1 Use of estimation and assumption

In the process of applying the entitys accounting policies, management had made the following estimation and
assumptions that have the significant effect on the amounts recognized in the financial statements. The estimates
and assumptions used in accompanying financial statements are based upon managements evaluation of the
relevant facts and circumstances as on the date of the financial statements, reviewed on an ongoing basis. Any
revision to accounting estimates is recognized prospectively in current and future periods.

a) Property, Plant and Equipment & Intangible Assets

Key estimates related to long-lived assets (property, plant and equipment and intangible assets) include useful
lives, recoverability of carrying values and the existence of any retirement obligations. As a result of future
decisions, such estimates could be significantly modified. The useful lives as mentioned in Note No. 4.2 and Note
No. 4.3 is applied as per Schedule II of Companies Act, 2013 and estimated based upon our historical experience,
technical estimates and industry information. These estimates include an assumption regarding periodic
maintenance and an appropriate level of annual capital expenditures to maintain the assets.

b) Employee Benefits - Measurement of Defined Benefit Obligation (DBO)

Management assesses post-employment and other employee benefit obligations using the projected unit credit
method based on actuarial assumptions which represent managements best estimates of the variables (such as
standard rates of inflation, medical cost trends, mortality, discount rate and anticipation of future salary increases)
that will determine the ultimate cost of providing post-employment and other employee benefits. Variation in
these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.

c) Income Taxes

The Group recognizes tax liabilities based upon self-assessment as per the tax laws. When the final tax outcome
of these matters is different from the amounts that were initially recognized, such differences will impact the
income tax and deferred tax provisions in the period in which such determination is made.

3.2 Critical judgements made in applying accounting policies
a) Revenue

The Group recognizes revenue from contracts with customers based on a five-step model as per Ind AS 115 which
involves judgements such as identification of distinct performance obligation involves judgement to determine the

deliverables and the ability of the customer to benefit independently from such deliverables. The management
exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a
period of time It considers indicators such as how customer consumes benefits as services are rendered or who
controls the asset as it is being created or existence of enforceable right to payment for performance to date and
alternate use of such product or service, transfer of significant risks and rewards to the customer, acceptance of
delivery by the customer, etc.

Revenue from services which is recognized over time using percentage-of-completion method. The management
uses judgement to estimate the services provided as on reporting date as a proportion of total services provided
which is used to determine the degree of the completion of the performance obligation.

b) Recognition of Deferred Tax Assets

The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the future
taxable income against which the deferred tax assets can be utilized. In addition, significant judgement is required
in assessing the impact of any legal or economic limits or uncertainties in various tax jurisdictions.

c) Recognition of Deferred Tax Liabilities on Undistributed Profits

The extent to which the Group can control the timing of reversal of deferred tax liability on undistributed profits
of its subsidiaries requires judgement.

d) Evaluation of Indicators for Impairment of Assets

The evaluation of applicability of indicators of impairment of assets requires assessment of several external and
internal factors which could result in deterioration of recoverable amount of the assets.

e) Expected Credit Losses

Expected credit losses of the Group are based on an evaluation of the collectability of receivables. A considerable
amount of judgement is required in assessing the ultimate realization of these receivables, including their current
credit worthiness, past collection history of each customer and ongoing dealings with them. If the financial
conditions of the counterparties with which the Group contracted were to deteriorate, resulting in an impairment
of their ability to make payments, additional expected credit loss may be required.

f) Useful Life of Depreciable/Amortizable Assets

Management reviews its estimate of the useful lives of depreciable/amortizable assets at each reporting date, based
on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence
that may change the utility of certain software, customer relationships, IT equipment and other plant and
equipment.

g) Fair Value Measurements

Management applies valuation techniques to determine the fair value of financial instruments (where active market
quotes are not available) and non-financial assets. This involves developing estimates and assumptions consistent
with how market participants would price the instrument. Management uses the best information available.
Estimated fair values may vary from the actual prices that would be achieved in an arms length transaction at the
reporting date.

h) Provisions

At each balance sheet date, basis the management judgement, changes in facts and legal aspects, the Group assess
the requirement of the provisions. However, the actual future outcome may be different from this judgement.

i) Leases

The Group determines the lease term as the non-cancellable term of the lease, together with any periods covered
by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to
terminate the lease, if it is reasonably certain not to be exercised. The Group has several lease contracts that include
extension and termination options. The Group applies judgement in evaluating whether it is reasonably certain or
not to exercise the option to renew or terminate the lease. That considers all relevant factors that create an economic
incentive for it to exercise either the renewal or termination. After the commencement date, the Group reassesses
the lease term if there is a significant event or change in circumstances that is within its control and affects its
ability to exercise or not to exercise the option to renew or to terminate.

4. Material Accounting Policy Information

1.1. Basis of Consolidation

Subsidiaries

The Subsidiaries, Gaudium International Private Limited and EKK Global Private Limited, are the Entities over
which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable
returns from its involvement with the entity and has the ability to affect those returns through its power to direct
the relevant activities of the entity. The Subsidiary is fully consolidated from the date on which control is
transferred to the Group. It is deconsolidated from the date that control ceases. Profit or loss and other
comprehensive income (‘OCI) of subsidiary acquired or disposed of during the period are recognized from the
effective date of acquisition, or up to the effective date of disposal, as applicable. The subsidiary has a consistent
reporting date of that of the Holding Company.

The Group combines the financial statements of the parent and its subsidiaries line by line adding together like
items of assets, liabilities, equity, income and expenses. Intergroup transactions, balances and unrealised gains on
transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset. Accounting policies of the subsidiaries is aligned
where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests, if any, presented as part of equity, represent the portion of a subsidiarys profit or loss
and net assets that is not held by the Group. Profit or loss and each component of OCI are attributed to the equity
holders of the Holding Company and to the non-controlling interests, if any, even if this results in the non-
controlling interests having a deficit balance. The Group attributes total comprehensive income or loss of
subsidiaries between the owners of the parent and the non-controlling interests, if any, based on their respective
ownership interests.

The Group treats transactions with non-controlling interests, if any that do not result in a loss of control as
transactions with equity owners of the group. A change in ownership interest results in an adjustment between the
carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the
subsidiaries. Any difference between the amount of the adjustment to non-controlling interests and any
consideration paid or received is recognized within equity.

Business Combinations

The Group applies the acquisition method in accounting for business combinations. The consideration transferred
by the Group to obtain control of a subsidiary is calculated as the sum of the acquisition-date fair values of assets
transferred, liabilities incurred and the equity interests issued by the Group, which includes the fair value of any
asset or liability arising from a contingent consideration arrangement. Acquisition costs are expensed as incurred.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are
measured initially at their acquisition date fair values.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the
amount recognized for non-controlling and any previous interest held, over the net identifiable assets acquired and
liabilities assumed. If the fair value of the net assets acquired is in excess of the aggregate consideration transferred,
the difference is recognized in OCI and accumulated in equity as capital reserve. However, if there is no clear
evidence of bargain purchase, the entity recognizes the gain directly in equity as capital reserve, without routing
the same through OCI.

Where settlement of any part of cash consideration is deferred, the amount payable in the future is discounted to
their present value as at the date of exchange. The discount rate used is the Groups incremental borrowing rate,
being the rate at which the similar borrowing could be obtained from an independent financier under comparable
terms and condition.

Contingent consideration is classified either as equity or financial liability. Amount classified as financial liability
are subsequently re-measured to fair value with changes in fair value recognized in profit or loss.

Business combinations involving entities or businesses under common control have been accounted for using the
pooling of interests method. The assets and liabilities of the combining entities are reflected at their carrying
amounts. No adjustments have been made to reflect fair values, or to recognize any new assets or liabilities except
changes made to harmonize the accounting policies.

1.2. Property, Plant and Equipment and Depreciation

Initial Recognition

All items of property, plant and equipment are initially measured at cost. The cost of an item of plant and equipment
is recognized as an asset if, and only if, it is probable that future economic benefits associated with the item will
flow to the Group and the cost of the item can be measured reliably.

Cost includes its purchase price (after deducting trade discounts and rebates), import duties & non-refundable
purchase taxes, any costs directly attributable to bringing the asset to the location & condition necessary for it to
be capable of operating in the manner intended by management, borrowing costs on qualifying assets and asset
retirement costs.

The activities necessary to prepare an asset for its intended use or sale extend to more than just physical
construction of the asset. It may also include technical (DPR, environmental, planning, Land acquisition and
geological study) and administrative work such as obtaining approvals before the commencement of physical
construction.

The cost of replacing a part of an item of property, plant and equipment is capitalized if it is probable that the
future economic benefits of the part will flow to the Group and that its cost can be measured reliably. The carrying
amount of the replaced part is derecognized.

Costs of day-to-day repairs and maintenance costs are recognized into the statement of profit and loss account as
incurred.

Subsequent measurement

Subsequent to recognition, property, plant and equipment are measured at cost less accumulated depreciation and
any accumulated impairment losses.

The carrying values of property, plant and equipment are reviewed for impairment when events or changes in
circumstances indicate that the carrying value may not be recoverable.

The residual values, estimated useful lives and depreciation method are reviewed at each financial year-end, and
adjusted prospectively, if appropriate.

Depreciation

Depreciation is provided on Straight Line Method, as per the provisions of Schedule II of the Companies Act, 2013
or based on useful life estimated on the technical assessment. Asset class wise useful lives are as under:

Type of Assets

Useful Life

Plant and Machinery

15 years

Operation Theatre Equipment

13 years

Furniture and Fixtures

10 years

Electrical Equipment

10 years

Motor Vehicles

8 years

Office Equipments

5 years

Computers

3 years

Leasehold Improvements

Over Lease Term

In respect of additions / deletions to the fixed assets / leasehold improvements, depreciation is charged from the
date the asset is ready to use / up to the date of deletion.

De-recognition

An item of plant and equipment is derecognized upon disposal or when no future economic benefits are expected
from its use or disposal. Any gain or loss arising on de-recognition of the asset is recognized in the profit or loss
in the year the asset is derecognized.

Capital Work in Progress and Capital Advances

Cost of asset not ready for intended use and assets under installation or under construction as at the Balance Sheet
date will be shown as Capital Work in Progress. Advances given towards acquisition of fixed assets outstanding
at each Balance Sheet date are disclosed as Other Non-Current Asset in accordance with Schedule III to the
Companies Act, 2013.

1.3. Intangible Assets & Amortization

Initial Recognition

Intangible assets acquired separately are initially measured at cost. Intangible assets are recognized if and only if,
it is probable that the future economic benefits that are attributable to the asset will flow to the Group and the cost
of the asset can be measured reliably.

Cost of separately acquired intangible assets includes its purchase price (after deducting trade discounts and
rebates), import duties & non-refundable purchase taxes, any costs directly attributable to preparing the asset for
its intended use.

Subsequent measurement and Amortization

Intangible assets are stated at cost of acquisition less accumulated amortization and accumulated impairment
losses, if any. Subsequent expenditure related to an item of intangible assets are added to its book value only if
they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

The carrying values of intangible assets are reviewed for impairment when events or changes in circumstances
indicate that the carrying value may not be recoverable.

The residual values, estimated useful lives and amortization method are reviewed at each financial year-end, and
adjusted prospectively, if appropriate

The useful lives of intangible assets are assessed as either finite or indefinite. Finite-life intangible assets are
amortised on a straight-line basis over the period of their estimated useful lives. Estimated useful lives by major
class of finite-life intangible assets are as follows

Intangible Assets

Method of Amortization Estimated Useful life

Trademarks

on straight-line basis 10 years

Software

on straight-line basis 3 years

The amortization expense is recognized in the statement of profit and loss unless such expenditure forms part of
carrying value of another asset.

Indefinite life intangible assets comprises of those assets for which there is no foreseeable limit to the period over
which they are expected to generate net cash inflows. These are considered to have an indefinite life, given the
strength and durability of the Company and the level of marketing support.

De-recognition

The amortization expense is recognized in the statement of profit and loss unless such expenditure forms part of
carrying value of another asset. Indefinite-life intangible assets comprises of those assets for which there is no
foreseeable limit to the period over which they are expected to generate net cash inflows.

These are considered to have an indefinite life, given the strength and durability of the Group and the level of
marketing support.

For indefinite life intangible assets, the assessment of indefinite life is reviewed annually to determine whether it
continues, if not, it is impaired or changed prospectively based on revised estimates.

1.4. Intangible Asset Under Development
Recognition and Initial Measurement

Intangible development costs are capitalized only when the following criteria are met:

• Technical and commercial feasibility is demonstrated

• Future economic benefits are probable

• The company intends and is able to complete and use or sell the asset

• The costs can be measured reliably

• Development costs are capitalized as an intangible asset if it can be demonstrated that prescribed
capitalisation criteria are met, the project is expected to generate future economic benefits, it is probable that
those future economic benefits will flow to the Company and the costs of the asset can be measured reliably,
else it is charged to the Statement of Profit and Loss.

Intangibles under development represent the costs incurred in the development of Gaudium Advanced Analysis and
Treatment (GAAT)

1.5. Inventories

Inventories of medicines, medical consumables and drugs are valued at lower of cost and net realizable value. Cost
of inventory includes cost of purchase and other costs incurred in bringing them to their present location and
condition. Net Realizable Value in respect of consumables is the estimated current procurement price in the
ordinary course of the business. Cost is determined on First in First Out (FIFO) basis.

4.5 Impairment of Non - Financial Assets

At each reporting date, the Group assesses whether there is any indication that an asset may be impaired. Where
an indicator of impairment exists, the Group makes a formal estimate of recoverable amount. Where the carrying
amount of an asset exceeds its recoverable amount the asset is considered impaired and is written down to its
recoverable amount.

Recoverable amount is the greater of fair value less costs to sell and value in use. It is determined for an individual
asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or
groups of assets, in which case, the recoverable amount is determined for the cash-generating unit to which the
asset belongs.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax
discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

Impairment losses of continuing operations, including impairment on inventories, are recognized in the statement
of Profit and Loss, except for properties previously revalued with the revaluation surplus taken to OCI. For such
properties, the impairment is recognized in OCI up to the amount of any previous revaluation surplus.

After impairment, depreciation or amortization is provided on the revised carrying amount of the asset over its
remaining useful life.

The impairment assessment for all assets is made at each reporting date to determine whether there is an indication
that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Group
estimates the assets or CGUs recoverable amount. A previously recognized impairment loss is reversed only if
there has been a change in the assumptions used to determine the assets recoverable amount since the last
impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed
its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had
no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of
profit or loss.

4.6 Financial Assets

Financial assets comprise of investments in equity and debt securities, mutual funds, loans, trade receivables, cash
and cash equivalents and other financial assets.

Initial Recognition

All financial assets except investments in associates and joint venture are recognized initially at fair value.
However, trade receivables that do not contain a significant financing component are measured at transaction price.
Purchases or sales of financial asset that require delivery of assets within a time frame established by regulation
or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Group
commits to purchase or sell the assets.

Subsequent Measurement

a. Financial assets measured at amortized cost:

Financial assets held within a business model whose objective is to hold financial assets in order to collect
contractual cash flows and the contractual terms of the financial assets give rise on specified dates to cash flows
that are solely payments of principal and interest on the principal amount outstanding are measured at amortised
cost using effective interest rate (EIR) method. The EIR amortization is recognized as finance income in the
Statement of Profit and Loss.

The Group while applying above criteria has classified the following at amortised cost:

a. Loans

b. Trade Receivable

c. Cash and Cash Equivalents

d. Other Financial Assets

b. Financial assets at fair value through other comprehensive income (FVTOCI):

Financial assets held within a business model whose objective is to hold financial assets in order to collect
contractual cash flows, selling the financial assets and the contractual terms of the financial assets give rise on
specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding
are measured at FVTOCI. Fair Value movements in financial assets at FVTOCI are recognized in other
comprehensive income. Equity instruments held for trading are classified at fair value through profit or loss
(FVTPL). For other equity instruments the Company classifies the same either at FVTOCI or FVTPL on
instrument to instrument basis. The classification is made on initial recognition and is irrevocable. Fair value
changes on equity investments at FVTOCI, excluding dividends are recognized in other comprehensive income
(OCI).

c. Financial assets at fair value through profit or loss (FVTPL)

Financial assets are measured at fair value through profit or loss if it does not meet the criteria for classification
as measured at amortised cost or at fair value through other comprehensive income. All fair value changes are
recognized in the statement of profit and loss.

d. Investments in joint ventures & associates, if any, are carried at cost in the Restated Consolidated Financial
Information. However, a provision for diminution in value is made to recognize a decline other than
temporary in value of the investments.

Impairment

Financial assets are tested for impairment based on the expected credit losses in accordance with Ind AS 109 on
the following financial assets:

a. Trade Receivables

An impairment analysis is performed at each reporting date. The expected credit losses over life time of the asset
are estimated by adopting the simplified approach using a provision matrix on its portfolio of trade receivables,
which is based on historical loss rates reflecting current condition and forecasts of future economic conditions. In
this approach assets are grouped on the basis of similar credit characteristics such as customer segment, past due
status and other factors which are relevant to estimate the expected cash loss from these assets.

b. Other financial assets

Other financial assets are tested for impairment based on significant change in credit risk since initial recognition
and impairment is measured based on probability of default over the life time when there is significant increase in
credit risk.

De-recognition

A financial asset is derecognized only when:

• The Group has transferred the rights to receive cash flows from the financial asset or

• The contractual right to receive cash flows from financial asset is expired or

• Retains the contractual rights to receive the cash flows of the financial asset but assumes a contractual
obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset and transferred substantially all risks and rewards of ownership of the
financial asset, in such cases the financial asset is derecognized. Where the entity has neither transferred a financial
asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is also
derecognized if the Group has not retained control of the financial asset.

4.7 Cash and Cash Equivalents

Cash and cash equivalents comprise cash at bank (including deposits with banks with original maturity of three
months or less) and cash in hand and short-term investments with an original maturity of three months or less.
Deposits with banks are subsequently measured at amortized cost and short-term investments are measured at fair
value through statement of profit & loss account.

4.8 Financial Liabilities
Initial Recognition

Financial liabilities are recognized when, and only when, the Group becomes a party to the contractual provisions
of the financial instrument. The Group determines the classification of its financial liabilities at initial recognition.
All financial liabilities are recognized initially at fair value plus any directly attributable transaction costs, such as
loan processing fees and issue expenses.

Subsequent Measurement - at amortised cost

After initial recognition, financial liabilities are subsequently measured at amortised cost using the effective
interest rate (EIR) method. Gains and losses are recognized in profit or loss when the liabilities are de recognized,
and through the amortization process.

De-recognition

A financial liability is de recognized when the obligation under the liability is discharged or cancelled or expired.
When an existing financial liability is replaced by another from the same lender on substantially different terms,
or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de
recognition of the original liability and the recognition of a new liability, and the difference in the respective
carrying amounts is recognized in profit or loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a
currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis,
to realize the assets and settle the liabilities simultaneously.

4.9 Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes
a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the
respective asset. Capitalisation of borrowing cost is suspended in the period during which the active development
is delayed due to other than temporary interruption. All other borrowing costs are expensed in the period they
occur. Borrowing costs consist of interest, exchange differences arising from foreign currency borrowings to the
extent they are regarded as an adjustment to the interest cost and other costs that an entity incurs in connection
with the borrowing of funds.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on
qualifying assets is deducted from the borrowing costs eligible for capitalization.

4.10 Employee benefits

Employee benefits are charged to the Statement of Profit and Loss for the year.

Retirement benefits in the form of Provident Fund are defined contribution scheme and such contributions are
recognized, when the contributions to the respective funds are due. There is no other obligation other than the
contribution payable to the respective funds

Gratuity liability is defined benefit obligation and is provided for on the basis of actuarial valuation on projected
unit credit method made at the end of each financial year. Re measurement in case of defined benefit plans gains
and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period
in which they occur, directly in other comprehensive income and they are included in the statement of changes in
equity.

Compensated absences are provided for on the basis of actuarial valuation on projected unit credit method made
at the end of each financial year. Re measurements as a result of experience adjustments and changes in actuarial
assumptions are recognized in statement of profit or loss account.

The amount of Non-current and Current portions of employee benefits is classified as per the actuarial valuation
at the end of each financial year.

4.12 Income Taxes

Income tax expense is comprised of current and deferred taxes. Current and deferred tax is recognized in net
income except to the extent that it relates to a business combination, or items recognized directly in equity or in
other comprehensive income. Current income tax relating to items recognized outside profit and loss is recognized
outside profit and loss (either in other comprehensive income or in equity). Current income taxes for the current
period, including any adjustments to tax payable in respect of previous years, are recognized and measured at the
amount expected to be recovered from or payable to the taxation authorities based on the tax rates that are enacted
or substantively enacted by the end of the reporting period.

Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax base using the tax rates that are expected
to apply in the period in which the deferred tax asset or liability is expected to settle, based on the laws that have
been enacted or substantively enacted by the end of reporting period.

Deferred tax assets and liabilities are not recognized if the temporary difference arises from goodwill or from the
initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects
neither the taxable income nor the accounting income. Deferred tax assets are generally recognized for all
deductible temporary differences to the extent that it is probable that taxable income will be available against
which they can be utilized. Deferred tax assets are reviewed at each reporting date and reduced accordingly to the
extent that it is no longer probable that they can be utilized.

Deferred tax assets and liabilities are offset when there is legally enforceable right of offset current tax assets and
liabilities when the deferred tax balances relate to the same taxation authority. Current tax asset and liabilities are
offset where the entity has legally enforceable right to offset and intends either to settle on a net basis, or to realize
the asset and settle the liability simultaneously. Deferred Tax relating to items recognized outside profit or loss is
recognized outside profit and loss (either in other comprehensive income or in equity).

4.13 Leases

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a
period of time in exchange for consideration.

Group as a lessee

The Group assesses whether a contract is or contains a lease, at inception of a contract. A contract is, or contains,
a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for
consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group
assesses whether:

i. the contract involves the use of an identified asset

ii. the Group has substantially all of the economic benefits from use of the asset through the period of the
lease, and

iii. the Group has the right to direct the use of the asset

The Groups lease assets consist of the following:

Asset Description

Useful life

Leasehold Building

As per Lease period

At date of commencement of leases, the Group recognized a right -of-use of asset (ROU) and a corresponding
lease liability for all the lease arrangements, except for those with a term of twelve month or less (short term leases)
and leases of low value assets. For these leases, the Group recognizes lease payments as an operating expense on
straight line basis over the lease term.

Initial Measurement

ROU assets are initially measured at cost that comprises of the initial amount of lease liability adjusted for any
lease payments made at or prior to the date of commencement, initial direct costs and lease incentives (if any).

Lease Liability is initially measured at the present value of future lease payments that are not paid at that date. The
lease payments shall be discounted using the interest the interest rate implicit in the lease or, if not readily
determinable, incremental borrowing rate.

Subsequent Measurement

ROU assets are subsequently measured at cost less accumulated depreciation and impairment loss, if any. ROU is
depreciated from the date of commencement on a straight-line basis over the shorter of lease term or useful life of
the underlying asset.

Lease Liability is subsequently measured by increasing the carrying amount to reflect interest and reducing the
carrying amount to reflect the lease payments made.

The carrying amount of lease liability is remeasured to reflect any reassessment or lease modification such as
change in lease term.

ROU asset and lease liability are separately presented in the balance sheet and lease payments have been classified
as financing cash flows.

Group as a lessor

Leases for which the Group is a lessor is classified as finance or operating lease. Leases in which the Group does
not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating
leases. Lease income from operating leases is recognized in the statement of profit and loss income on a straight-
line basis over the lease term unless the receipts are structured to increase in line with expected general inflation
to compensate for the expected inflationary cost increases. The respective leased assets are included in the
balance sheet based on their nature.

4.14 Provisions

A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation
that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the
obligation. Provisions are measured at the present value of managements best estimate of the expenditure required
to settle the present obligation at the end of the reporting period.

The Group recognizes decommissioning provisions in the period in which a legal or constructive obligation is
incurred. A corresponding decommissioning cost is added to the carrying amount of the associated property, plant
and equipment, and it is depreciated over the estimated useful life of the asset.

4.15 Contingent Liabilities

Contingent liability is disclosed in case of:

• A present obligation arising from past events, when it is not probable that an outflow of resources will be
required to settle the obligation;

• A present obligation arising from past events, when no reliable estimate is possible;

• A possible obligation arising from past events whose existence will be confirmed by the occurrence or non-
occurrence of one or more uncertain future events beyond the control of the Group where the probability of
outflow of resources is not remote.

4.16 Contingent Assets

Contingent assets are not recognized but disclosed in the financial statements when an inflow of economic benefits
is probable.

4.17 Fair Value Measurements

Group follows the following mentioned underneath hierarchy for determining fair values of its financial
instruments:

• Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;

• Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability,
either directly (prices) or indirectly (derived from prices); and

• Level 3 - Inputs for the asset or liability that are not based on observable market data.

The fair value of financial instruments traded in active markets is based on quoted market prices at the reporting
dates. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer,
broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly
occurring market transactions on an arms length basis. The fair value for these instruments is determined using
Level 1 inputs.

The fair value of financial instruments that are not traded in an active market (for example, over the counter
derivatives) is determined by using valuation techniques. These valuation techniques maximize the use of
observable market data where it is available and rely as little as possible on entity specific estimates. If all
significant inputs required to fair value an instrument are observable, the instrument is fair valued using level 2
inputs.

If one or more of the significant inputs is not based on observable market data, the instrument is fair valued using
Level 3 inputs. Specific valuation techniques used to value financial instruments include:

• Quoted market prices or dealer quotes for similar instruments

• The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based
on observable yield curves

• The fair value of forward foreign exchange contracts is determined using forward exchange rates at the
reporting dates, with the resulting value discounted back to present value

• Other techniques, such as discounted cash flow analysis, are used to determine fair value for the remaining
financial instruments.

4.18 Revenue Recognition

Sale of Services: The Group derives revenues primarily from business of providing IVF treatment in bundled
packages which includes injections, Ovum/Egg pickup, Embryo Creation and Embryo Transfer. Revenue from
service transactions is usually recognised as the service is performed, either by proportionate completion method
or by the completed service contract method.

Sale of Products: Revenue is measured at the fair value of the consideration received or receivable for goods
supplied, net of returns and discounts to customers. Revenue from sale of goods is recognised on transfer of
significant risks and rewards of ownership to the buyer, which generally coincides with the delivery of goods to
customers.

The Group recognizes revenue from contracts with customers based on a five-step model, such as to, identifying
the contracts with a customer, identifying the performance obligations in the contract, determine the transaction
price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or
as) the entity satisfies a performance obligation at a point in time or over time.

The Group satisfies a performance obligation and recognizes revenue over time, if one of the following criteria is
met:

• The customer simultaneously receives and consumes the benefits provided by the Groups performance as
the Group performs; or

• The Groups performance creates or enhances an asset that the customer controls as the asset is created or
enhanced; or

• The Groups performance does not create an asset with an alternative use to the Group and the entity has an
enforceable right to payment for performance completed to date.

For performance obligations where one of the above conditions are not met, revenue is recognized at the point in
time at which the performance obligation is satisfied.

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that
reflects the consideration we expect to receive in exchange for those products or services.

4.19 Other Income
Interest Income

For all debt instruments measured either at amortised cost or at fair value through other comprehensive income,
interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the
estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period,
where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability.
When calculating the effective interest rate, the Group estimates the expected cash flows by considering all the
contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) but
does not consider the expected credit losses. Interest income is included in finance income in the statement of
profit and loss.

Interest income on fixed deposits is recognized on a time proportion basis taking into account the amount
outstanding and the applicable interest rate.

Dividend income

Dividend income is recognized at the time when right to receive the payment is established, which is generally
when the shareholders approve the dividend and it is probable that the economic benefit associate with the dividend
will flow to the Group, and the amount of the dividend can be measured reliably.

4.20 Foreign currency transactions
Functional and presentation Currency

The Financial statements are presented in Indian Rupee which is also the functional and presentation currency
of the Group.

Transaction and Balances

Transactions in foreign currencies are translated to the functional currency of the Group, at exchange rates in effect
at the transaction date. At each reporting date monetary assets and liabilities denominated in foreign currencies are
translated at the exchange rate in effect at the date of the financial statement. The translation for other non-
monetary assets and liabilities are not updated from historical exchange rates unless they are carried at fair value.

4.21 Earnings per share

Basic earnings per share are calculated by dividing the profit attributable to owners of the Group by the weighted
average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares
issued during the year and excluding treasury shares.

Diluted earnings per share adjust the figures used in the determination of basic earnings per share to take into
account, the after income tax effect of interest and other financing costs associated with dilutive potential equity
shares and the weighted average number of additional equity shares that would have been outstanding assuming
the conversion of all dilutive potential equity shares.

4.22 Segment Reporting

Operating segments are identified and reported in a manner consistent with the internal financial reporting provided
to the chief operating decision makers responsible for allocating resources and assessing performance of the
operating segments.

4.23 Events after reporting date

Where events occurring after the Balance Sheet date provide evidence of conditions that existed at the end of the
reporting period, the impact of such events is adjusted within the Restated Consolidated Financial Information.
Non adjusting events after the Balance Sheet date which are material in size or nature are disclosed separately in
the Restated Consolidated Financial Information.

Results of Operations

The following table sets forth select financial data from our restated consolidated statement of profit and loss for the
six months period ended Fiscal 2025, Fiscals 2024, and fiscal 2023 the components of which are also expressed as a
percentage of total income for such years/ period

Rs in Lakhs

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Revenue from Operations

7,072.40 4,789.01 4,423.69

As % of Total Income

99.67%

99.45%

99.95%

Other Income

23.44 26.30 2.33

As % of Total Income

0.33%

0.55%

0.05%

Total Income

7,095.84 4,815.31 4,426.02

EXPENSES

Cost of Rendering Services

525.33 513.35 357.53

As % of Total Income

7.40%

10.66%

8.08%

Purchase of Medical Consumable and Drugs

2,020.60 517.65 594.46

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

As % of Total Income

28.48%

10.75%

13.43%

Changes in Inventories of Medical Consumable and Drugs

(512.68) (62.78) (98.58)

As % of Total Income

-7.23%

-1.30%

-2.23%

Employee benefits expenses

745.67 635.38 569.23

As % of Total Income

10.51%

13.19%

12.86%

Finance cost

139.09 74.75 34.24

As % of Total Income

1.96%

1.55%

0.77%

Depreciation and Amortization expense

204.69 215.86 143.40

As % of Total Income

2.88%

4.48%

3.24%

Other expenses

1,430.90 1,257.94 994.50

As % of Total Income

20.17%

26.12%

22.47%

Total Expenses

4,553.59 3,152.15 2,594.78

As % of Total Income

64.17%

65.46%

58.63%

Profit / (Loss) before Exceptional Items and Tax

2,542.25 1,663.16 1,831.24

As % of Total Income

35.83%

34.54%

41.37%

Exceptional Items

- - -

As % of Total Income

0.00%

0.00%

0.00%

Profit / (Loss) before Tax

2,542.25 1,663.16 1,831.24

As % of Total Income

35.83%

34.54%

41.37%

Tax Expense

(a) Current tax

613.27 586.37 456.59

(b) Deferred tax

16.24 45.10 22.11

Total Tax Expense

629.51 631.47 478.70

As % of Total Income

8.87%

13.11%

10.82%

Profit / (Loss) for the Period

1,912.74 1,031.68 1,352.54

As % of Total Income

26.96%

21.43%

30.56%

Other Comprehensive Income

A (i) Items that will not be reclassified to profit and loss

18.39 28.96 (9.00)

Total Comprehensive Income for the period

1,931.13 1,060.66 1,343.54

Earnings Per Equity Share

Basic EPS

3.12 1.68 2.20

Diluted EPS

3.12 1.68 2.20

Principal Components of Income and Expenditure:

? Total Income/ Revenue

Total income comprises of (i) Revenue from Operations and (ii) Other Income

1) Revenue from Operations: Revenue from operation consist of Revenue from rendering of Healthcare Services
and Sale of Products

2) Other Income: Other income of our company comprises of Interest Income from Bank, Other professional
receipts and Unclaimed Balances and Excess Provisions Written Back

? Expenses

Total Expenses includes (i) Cost of Rendering Services, (ii) Purchase of Medical Consumable and Drugs, (iii)
Changes in Inventories of Medical Consumable and Drugs, (iv) Employee benefits expenses, (v) Finance cost
(vi) Depreciation and Amortization Expense and (vii) Other expenses.

Component of Total Income:

Total Revenue / Income

(f In Lakhs)

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Revenue from Operation

7,072.40 4,789.01 4,423.69

As % of Total Revenue

99.67%

99.45%

99.95%

Other Income

23.44 26.30 2.33

As % of Total Revenue

0.33%

0.55%

0.05%

Total Revenue / Income

7,095.84 4,815.31 4,426.02

The Total Revenue of our company was ?7095.84 lakhs in fiscal 2025, ?4,815.31 lakhs in fiscal 2024 and ?4,426.02
lakhs in fiscal 2023.

Total revenue consists of Revenue from operations and Other Income, our company has reported the Revenue from
operations of ?7,072.40 lakhs, ?4,789.01 lakhs and ?4,423.69 lakhs for the fiscal 2025, fiscal 2024 and fiscal 2023
respectively. Revenue from operations contributes 99.67%, 99.45% and 99.95% of the total income for the fiscal 2025,
fiscal 2024 and fiscal 2023 respectively.

Company has earned the Other income of ?23.44 lakhs, ?26.30 lakhs and ?2.33 lakhs for the fiscal 2025, fiscal 2024
and fiscal 2023 respectively. Other income contributes 0.33%, 0.55% and 0.05% of the total income for the fiscal
2025, fiscal 2024 and fiscal 2023 respectively.

The following is the Income mix of Revenue from Operations:

(f in Lakhs)

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Revenue from Operation

Revenue from rendering of Healthcare Services

5,900.16 4,593.81 4,401.43

As % of Revenue from Operations

83.43%

95.92%

99.50%

Sale of Products

1,172.24 195.20 22.26

As % of Revenue from Operations

16.57%

4.08%

0.50%

Total Revenue from Operations

7,072.40 4,789.01 4,423.69

Our revenue from operations comprise of Revenue from rendering of Healthcare Services and Sales of products.
Revenue from rendering of Healthcare Services was ?5,900.16 lakhs in fiscal 2025, ?4,593.81 lakhs in fiscal 2024
and ?4,401.43 lakhs in fiscal 2023. Revenue from rendering of Healthcare Services as percent of Revenue from
operations was 83.43% in fiscal 2025, 95.92% in fiscal 2024 and 99.50% in fiscal 2023.

The following is the mix of Other Income:

(f in Lakhs)

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Interest Income

From Bank

0.47 0.40 0.48

From Income Tax Refund

- 0.89 -

Loan Given

22.44 - -

Total Interest Income

22.91 1.29 0.48

As % of Total Other Income

97.74%

4.90%

20.60%

Other Professional Receipts

- - 1.85

As % of Total Other Income

0.00%

0.00%

79.40%

Unclaimed Balances and Excess Provisions Written Back

0.53 25.01 -

As % of Total Other Income

2.26%

95.10%

0.00%

Total Other Income

23.44 26.30 2.33

Our Other income for fiscal 2025, fiscal 2024 and fiscal 2023 was reported at ?23.44 lakhs, ?26.30 lakhs and ?2.33
lakhs respectively. Other income primarily comprise of Interest income from banks, income tax refund, other
professional receipts and Unclaimed Balances and Excess Provisions Written Back.

The following is the mix of Total Expenses

(f in Lakhs)

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Cost of Rendering Services

525.33 513.35 357.53

As % of Total Expenditure

11.54%

16.29%

13.78%

Purchase of Medical Consumable and Drugs

2,020.60 517.65 594.46

As % of Total Expenditure

44.37%

16.42%

22.91%

Changes in Inventories of Medical Consumable and Drugs

(512.68) (62.78) (98.58)

As % of Total Expenditure

-11.26%

-1.99%

-3.80%

Employee benefits expenses

745.67 635.38 569.23

As % of Total Expenditure

16.38%

20.16%

21.94%

Finance cost

139.09 74.75 34.24

As % of Total Expenditure

3.05%

2.37%

1.32%

Depreciation and Amortization Expense

204.69 215.86 143.40

As % of Total Expenditure

4.50%

6.85%

5.53%

Other expenses

1,430.90 1,257.94 994.50

As % of Total Expenditure

31.42%

39.91%

38.33%

Total Expenditure

4,553.59 3,152.15 2,594.78

Fiscal 2025 as Compared to Fiscal 2024
Total Income/Revenue

Total income for fiscal 2025 was reported at Rs7,095.84 lakhs which comprised of Revenue from operations of
Rs7,072.40 lakhs and other income of Rs23.44 lakhs. Total income has grown by Rs2,280.53 lakhs and by 47.36%
compared to total income of Rs4,815.31 lakhs in fiscal 2024. Increase in total income was result of increase in revenue
from operations by Rs2,283.39 lakhs and by 47.83% compared to fiscal 2024.

Revenue from Operations

Revenue from operations for fiscal 2025 was reported was Rs7,072.40 lakhs that has increased by Rs2,283.39 lakhs and
by 47.68% compared to Rs4,789.01 lakhs in fiscal 2024. Also there been higher realisation of ET transfer, which led
to the rise in revenue from operations.

Revenue from operations comprised Revenue from rendering of Healthcare Services of Rs 5,900.16 lakhs, which
increased by Rs1,306.35 lakhs and by 28.44% from fiscal 2024 and Sale of Products was Rs1,172.24 lakhs which
increased by Rs977.04 lakhs and by 500.53% from fiscal 2024. Revenue from rendering of Healthcare Services and
Sale of Products was 83.43% and 16.57% of Revenue from operations.

Major contribution in revenue from rendering of health care services came from IVF treatment which grown by
31.45% compared to last year to Rs5,554.38. Revenue from hospital was Rs345.78 lakhs and revenue from pharmacy
was contributed to Rs1,172.24 lakhs and 16.57% of the revenue from operations. Increase in Revenue from operations
was mainly supported by number of Embryo transfer, the number of embryo transfer has increased by 29.08% to 1,913
in fiscal 2025 compared to 1,482 in fiscal 2024.

Our company has performed 1,563 Ovum pickup and 1,913 Embryo transfer during fiscal 2025. We have realised
Average revenue per patient of Rs1.60 lakhs which decreased by 56.76% over the fiscal 2024. Also number of cycle
performed during the fiscal 2025 declined by 6.33% to 3,476 cycle compared to 3,711 cycle in fiscal 2024.

Revenue from pharmacy has increased significantly by 500.56% to Rs1,172.24 lakhs in fiscal 2024 compared to
Rs195.19 lakhs in fiscal 2024

Total Expenses

Total Expenses for fiscal 2025 was Rs4,553.59 lakhs, which has increased by 44.46% and by ^1,401.44 lakhs compared
to Rs3,152.15 lakhs in fiscal 2024. Total expenses as a percent of total revenue was 64.17% which has gone down by
1.29% from fiscal 2024. Total expenses of company for the said period comprised of Cost of Rendering Services,
Purchase of Medical Consumable and Drugs, Changes in Inventories of Medical Consumable and Drugs, Employee
Benefits Expense, Finance Cost, Depreciation and Amortization Expense and Other Expenses.

Cost of Rendering Services

Cost of rendering Services for fiscal 2025 was Rs525.33 lakhs compared to Rs513.35 lakhs in fiscal 2024, it has increased
by ^11.98 lakhs and by 2.33% fiscal 2024. This primarily consists of fee paid to professional consultant doctors for
treatment. Cost of rendering Services is 11.54% to the total expenditure and 7.40% to the Total Revenue during the
fiscal 2025.

Purchase of Medical Consumable and Drugs

Purchase of Medical Consumable and Drugs for fiscal 2025 was recorded at Rs2,020.60 lakhs compared to Rs517.65
lakhs in fiscal 2024, for fiscal 2025 it has increased by Rs1,502.94 lakhs and by 290.34% from fiscal 2024. Purchase
of Medical Consumable and Drugs as a percent of total expenditure and total revenue was 44.37% and 28.48%
respectively. As percent of total revenue, purchases has increased from 10.75% in fiscal 2024 to 28.48% in fiscal
2025.

Changes in Inventories

Change in inventory for fiscal 2025 was negative to the extent of Rs512.68 lakhs. We had aggregate opening inventory
of Rs210.27 lakhs in fiscal 2025 compared to Rs149.96 lakhs in fiscal 2024. Closing inventory for fiscal 2025 was
Rs722.95 lakhs compared to Rs210.27 lakhs in fiscal 2024.

Employee Benefit Expenses

Employee benefit expenses for fiscal 2025 was Rs745.67 lakhs which increased by Rs110.29 lakhs and by 17.36%
compared to Rs635.38 lakhs in fiscal 2024. Major part of the employee expense was Salaries, allowances and benefits
to employees of Rs701.09 lakhs, Contribution to provident and other fund Rs19.91 lakhs and Rs24.67 lakhs towards Staff
Welfare Expense. Employee benefit expenses primarily increased due to increase in number of Doctors and Admin,
Managerial and Support Staffs and general hike in salaries. However, as percent of total revenue, the employee cost
decreased to 10.51% in fiscal 2025 compared to 13.19% in fiscal 2024.

Finance Cost

Company has incurred Rs139.09 lakhs as finance cost in fiscal 2025. Finance cost comprised of Rs123.61 lakhs towards
the interest on bank borrowings and Rs15.48 lakhs for lease liabilities. Finance cost increased by Rs64.34 lakhs and by
86.07% from Rs74.75 lakhs in fiscal 2024. Increase in interest payment was resulted from increase in Drop down
overdraft facility from bank under short term borrowings to manage the working capital, this has increased from
^1,361.10 lakhs in fiscal 2024 to Rs1,493.91 lakhs in fiscal 2025. Also, there was Overdraft used for Rs206.91 lakhs.

Depreciation and Amortisation

Depreciation and amortisation of Rs204.69 lakhs were charged during fiscal 2025, which has decreased by Rs 11.17 lakhs
and by 5.17% compared to Rs215.86 lakhs in fiscal 2024. As a part of total depreciation, Rs72.55 lakhs was charged as
Depreciation on Property, Plant and Equipment, Rs108.05 lakhs for Amortization of Intangible Assets and Rs24.09 lakhs
was charged for Depreciation on ROU Asset. Depreciable asset consists of Property, Plant and Equipment, Other

Intangible Assets and Right of Use Assets. Major part of depreciation is Amortization of Intangible Assets, for fiscal
2024, Gross block of other intangible assets was Rs738.50 lakhs which comprises of Rs738.82 lakhs was towards
Development of SOP.

Other Expenses

Other expenses accounted to Rs1,430.90 lakhs during fiscal 2025, which increased by Rs172.96 lakhs and by 13.75%
compared to Rs1,257.94 lakhs in fiscal 2024. Other expenses as percent of total income was 20.17% in fiscal 2025
compared to 26.12% in fiscal 2024. Major part of the other expenses was Advertisement expenses which increased
by Rs14.75 lakhs to Rs584.89 lakhs, Legal & Professional expenses increased by Rs85.85 lakhs to Rs199.64 lakhs and
Rent Expenses increased by Rs18.90 lakhs to Rs250.20 lakhs. These major expenses contributed 72.31% to the total of
other expenses during fiscal 2025.

Profit / (loss) Before Tax

Profit before tax (PBT) for fiscal 2025 was Rs2,542.25 lakhs which increased by Rs879.09 lakhs and by 52.86%
compared to Rs1,663.16 lakhs in fiscal 2024. Profitability has increased with increase in revenue in absolute terms and
also, fall in total expenditure as percent of revenue from 65.46% in fiscal 2024 to 64.17% in fiscal 2025, also increase
in revenue from pharmacy has positively impacted overall profitability.

Tax Expenses

Total tax expenses of Rs629.51 lakhs were incurred in fiscal 2025. It consists of Rs613.27 lakhs towards current taxes
and Rs16.24 lakhs towards Deferred Tax.

Profit / (loss) After Tax

Profit after tax for the Rs1,912.74 lakhs were reported for fiscal 2025, which increased by Rs881.06 lakhs and by 85.40%
compared to ^1,031.69 lakhs in fiscal 2024. Profit after tax as percent of total income or profit margin was 26.96% in
fiscal 2025 compared to 21.43% in fiscal 2024.

Fiscal 2024 as Compared to Fiscal 2023

Total Income/Revenue

Total income for fiscal 2024 was reported at Rs4,815.31 lakhs which comprised of Revenue from operations of
Rs4,789.01 lakhs and other income of Rs26.30 lakhs. Total income has grown by Rs389.29 lakhs and by 8.80% compared
to total income of Rs4,426.02 lakhs in fiscal 2023. Increase in total income was result of increase in revenue from
operations by Rs365.32 lakhs and by 8.26% compared to fiscal 2023.

Revenue from Operations

Revenue from operations for fiscal 2024 was reported was Rs4,789.01 lakhs that has increased by Rs365.32 lakhs and
by 8.26% compared to Rs4,423.69 lakhs in fiscal 2023.

Revenue from operations comprised Revenue from rendering of Healthcare Services of Rs 4,593.81 lakhs, which
increased by Rs192.38 lakhs and by 4.37% from fiscal 2023 and Sale of Products was Rs195.20 lakhs which increased
by Rs172.94 lakhs and by 365.32% from fiscal 2023. Revenue from rendering of Healthcare Services and Sale of
Products was 95.92% and 4.08% as percent of Revenue from operations.

Major contribution in revenue from rendering of health care services came from IVF treatment which comprised of
88.17% of revenue from operations to Rs4,015.24 lakhs which increased by 5.16% compared to Rs4,222.42 lakhs in
fiscal 2024. Revenue from hospital was Rs371.39 lakhs and revenue from pharmacy was Rs195.20 lakhs.

Our company has performed 2,229 Ovum pickup and 1,482 Embryo transfer during fiscal 2024. We have realised
Average revenue per patient of Rs3.70 lakhs which increased by 6.32% over the fiscal 2023. Also number of cycle
performed during the fiscal 2024 increased by 5.67% to 3,711 cycle compared to fiscal 2023. These are the major
factors which contributed to increase in revenue from operations.

Total Expenses

Total Expenses for fiscal 2024 was Rs3,152.15 lakhs, which has increased by 21.48% and by Rs557.37 lakhs compared
to Rs2,594.86 lakhs in fiscal 2023. Total expenses as a percent of total revenue was 65.46% which has gone up 6.84%
from 58.63% in fiscal 2023. Total expenses of company for the said period comprised of Cost of Rendering Services,
Purchase of Medical Consumable and Drugs, Changes in Inventories of Medical Consumable and Drugs, Employee
Benefits Expense, Finance Cost, Depreciation and Amortization Expense and Other Expenses.

Decrease in purchase of medical consumables and drugs was the prime reason for fall in total expenses.

Cost of Rendering Services

Cost of rendering Services for fiscal 2024 was Rs513.35 lakhs compared to Rs357.53 lakhs in fiscal 2023, for fiscal
2024 it has increased by Rs155.82 lakhs and by 43.58% from fiscal 2023. This primarily consists of fee paid to
professional consultant doctors for treatment. Cost of rendering Services as percent is 12.23% to the total expenditure
and 8.45% to the Total Revenue during the fiscal 2024. Cost of rendering Services has increased due to increase in
number of OPU and number of cycled performed.

Purchase of Medical Consumable and Drugs

Purchase of Medical Consumable and Drugs for fiscal 2024 was Rs517.65 lakhs compared to Rs594.46 lakhs in fiscal
2023, for fiscal 2024 it has decreased by Rs76.81 lakhs and by 12.92% from fiscal 2023. Purchase of Medical
Consumable and Drugs as a percent of total expenditure and total revenue was 16.42% and 10.75% respectively. As
percent of total income, purchases has fallen from 13.43% in fiscal 2023 to 10.75% in fiscal 2024. Purchases during
the year was lower because of higher inventory received from last fiscal.

Changes in Inventories

Change in inventory for fiscal 2024 was Rs(62.78) lakhs. We had aggregate opening inventory of Rs 149.96 lakhs in
fiscal 2024 compared to Rs48.91 lakhs in fiscal 2023. Closing inventory for fiscal 2024 was Rs210.27 lakhs compared
to Rs 147.49 lakhs in fiscal 2023.

Employee Benefit Expenses

Employee benefit expenses for fiscal 2024 was Rs635.38 lakhs which increased by Rs66.15 lakhs and by 11.62%
compared to Rs569.23 lakhs in fiscal 2023. Major part of the employee expense was Salaries, allowances and benefits
to employees of Rs601.60 lakhs, Contribution to provident and other fund Rs18.43 lakhs and Rs15.35 lakhs towards Staff
Welfare Expense. Employee benefit expenses primarily increased due to increase in number of Doctors and Admin,
Managerial and Support Staffs and general hike in salaries. However, as percent of total revenue the employee cost
increased to 13.19% compared to 12.86% in fiscal 2023.

Finance Cost

Company has incurred Rs74.74 lakhs as finance cost in fiscal 2024. Finance cost comprised of Rs59.40 lakhs towards
the interest on bank borrowings and Rs15.35 lakhs for lease liabilities. Finance cost increased by Rs40.51 lakhs and by
118.31% from Rs34.24 lakhs in fiscal 2023. Increase in interest payment was resulted from increase in Drop down
overdraft facility from bank under short term borrowings to manage the working capital, this has increased from
Rs750.89 lakhs in fiscal 2023 to ^1,361.80 lakhs in fiscal 2024.

Depreciation and Amortisation

Depreciation and amortisation of Rs215.86 lakhs were charged during fiscal 2024, which has increased by Rs72.46 lakhs
and by 50.53% compared to Rs143.40 lakhs in fiscal 2023. As a part of total depreciation, Rs69.17 lakhs was charged
as Depreciation on Property, Plant and Equipment, Rs127.01 lakhs for Amortization of Intangible Assets and Rs19.68
lakhs was charged for Depreciation on ROU Asset. Depreciable asset consists of Property, Plant and Equipment,
Other Intangible Assets and Right of Use Assets. Major part of depreciation is Amortization of Intangible Assets, for
fiscal 2024, Gross block of other intangible assets was Rs1,264.11 lakhs which comprises of Rs1,249.72 lakhs of
trademarks and Rs14.39 lakhs of Softwares. Also there was addition on lease hold improvement of Rs203.34 lakhs
under Property, Plant & Equipments on account of opening of new centre and revamp of two existing centre.

Other Expenses

Other expenses accounted to Rs1,257.94 lakhs during fiscal 2024, which increased by Rs263.44 lakhs and by 6.49%
compared to Rs994.50 lakhs in fiscal 2023. Other expenses as percent of total income was 26.12% in fiscal 2024
compared to 22.47% in fiscal 2023. Major part of the other expenses was Advertisement expenses which increased
by Rs240.45 lakhs to Rs570.14 lakhs, CSR expenses increased by Rs15.05 lakhs to Rs23.38 lakhs, Legal & Professional
expenses increased by Rs36.06 lakhs to ^113.79 lakhs and Rent Expenses increased by Rs19.74 lakhs to Rs61.24 lakhs.
These major expenses contributed 74.61% to the total of other expenses during fiscal 2024.

Profit / (loss) Before Tax

Profit before tax (PBT) for fiscal 2024 was Rs 1,663.16 lakhs which decreased by Rs 168.08 lakhs and by 9.18% compared
to ^1,831.16 lakhs in fiscal 2023. Profitability has decreased marginally due to higher cost of rendering services and
increase in overall total expenses.

Tax Expenses

Total tax expenses of Rs 631.47 lakhs were incurred in fiscal 2024. It consists of Rs586.36 lakhs towards current taxes
and Rs45.10 lakhs towards Deferred Tax.

Profit / (loss) After Tax

Profit after tax for the Rs 1,031.69 lakhs were reported for fiscal 2024, which decreased by Rs320.86 lakhs and by 23.72%
compared to Rs1,352.46 lakhs in fiscal 2023. Profit after tax as percent of total income or profit margin was 21.43%.

Analysis of Cash Flow Statement

Rs in Lakhs

Particulars

Fiscal 2025 Fiscal 2024 Fiscal 2023

Net Cash Flow Generated from Operating Activities

871.76 344.06 2,385.34

Net Cash Flow from Investing Activities

(1,517.42) (540.16) (1,562.68)

Net Cash Flow from Financing Activities

181.66 (124.11) 525.45

Net Increase In Cash and Cash Equivalents

(464.00) (320.21) 1,348.11

Opening Cash and Cash Equivalents

1,185.50 1,505.71 157.60

Closing Cash and Cash Equivalents

721.50 1,185.50 1,505.71

Net Cash Flow Generated from Operating Activities

Fiscal 2025

Net Cash Flow from operations was Rs871.76 lakhs, operating profit before working capital was Rs2,907.45 lakhs post
adjusting of Depreciation and amortization expense and other non-operating income and expenses collectively
amounting to Rs346.81 lakhs. Cash used in current assets was collectively increased by Rs2,905.42 lakhs adjusted of

increase in current liabilities of Rs1,338.43 lakhs. Post adjustment of working capital change and taxes, the cash
generated from operations was Rs871.76 lakhs.

Fiscal 2024

Net Cash Flow from operations was Rs344.06 lakhs, operating profit before working capital was Rs1,962.96 lakhs post
adjusting of Depreciation and amortization expense and other non-operating income and expenses collectively
amounting to Rs270.84 lakhs. Cash used in current assets was collectively increased by Rs1,439.13 lakhs adjusted of
increase in current liabilities of Rs2.70 lakhs. Post adjustment of working capital change and taxes, the cash generated
from operations was Rs344.06 lakhs.

Fiscal 2023

Net Cash Flow from operations was Rs2,385.34 lakhs, operating profit before working capital was Rs1,999.40 lakhs
post adjusting of Depreciation and amortization expense and other non-operating income and expenses collectively
amounting to Rs177.16 lakhs. Cash generated from current assets was collectively amounted to Rs860.98 lakhs adjusted
of decrease in current liabilities of Rs0.11 lakhs. Post adjustment of working capital change and taxes, the cash
generated from operations was Rs2,385.34 lakhs.

Net Cash Flow Generated from Investing Activities

For 2025

Net Cash Flow generated from Investing Activities was negative to the extent of Rs1,517.42 lakhs. This was primarily
on Purchase of Property, Plant and Equipment and Intangible Assets including ROU by Rs887.84 lakhs, purchase of
non-current investment of Rs500.00 lakhs, decrease in corporate loan by Rs400 lakhs, increase in non current despoit by
Rs2.50, capital advances to related party of Rs250 lakhs and Interest Received from Banks on Bank Deposits of Rs22.92
lakhs.

Fiscal 2024

Net Cash Flow generated from Investing Activities was negative to the extent of Rs540.16lakhs. This was primarily on
Purchase of Property, Plant and Equipment and Intangible Assets including ROU by Rs278.66 lakhs, increase in capital
advances of Rs250 lakhs, decrease in non-current investment of Rs0.10 lakhs, increase in non-current deposits by Rs12
lakhs and Interest Received from Banks on Bank Deposits of Rs0.40 lakhs.

Fiscal 2023

Net Cash Flow generated from Investing Activities was negative to the extent of Rs1,562.68 lakhs. This was primarily
on Purchase of Property, Plant and Equipment and Intangible Assets including ROU by Rs1,525.64 lakhs, purchase of
investment of Rs37.29 lakhs adjusted of Interest Received from Banks on Bank Deposits of Rs0.25 lakhs.

Net Cash Flow Generated from Financing Activities

Fiscal 2025

Net Cash Flow generated from Financing Activities was Rs181.66 lakhs. This was primarily on account of proceeds
from net borrowing to the extent of Rs320.75 lakhs, interest payment of Rs139.09 and Repayment of Lease Liabilities
of Rs0.17 lakhs.

Fiscal 2024

Net Cash Flow used in Financing Activities was Rs124.11 lakhs. This was primarily due dividend payment of Rs635.00
lakhs, interest payment of Rs74.75 lakhs, repayment of lease liabilities of Rs8.76 lakhs adjusted for increase in net
borrowings by Rs594.40 lakhs.

Fiscal 2023

Net Cash Flow Generated from Financing Activities was Rs525.45 lakhs. This was primarily on net cash inflows
increase due to increase in net borrowings by Rs383.30 lakhs and repayment of lease liabilities of Rs176.39 lakhs
adjusted for cash outflow due to interest payment of Rs34.24 lakhs.

Quantitative and Qualitative Disclosures about Risks

Capital Management

The objective of the Groups capital management structure is to ensure sufficient liquidity to support its business, to
ensure the Groups ability to continue as a going concern and provide adequate return to shareholders. The Group
monitors capital and the long term cash flow requirements including externally imposed capital requirements of the
business on the basis of the carrying amount of equity less cash and cash equivalents as presented on the face.
Management assesses the Groups capital requirements in order to maintain an efficient overall financing structure
while avoiding excessive leverage. This takes into account the subordination levels of the Groups various classes of
debt. The Group manages the capital structure and makes adjustments to it in the light of changes in economic
conditions and the risk characteristics of the underlying assets.

Particulars

As at

31st March2025

As at

31st March
2024

Net Debts (Net of Cash and Cash Equivalents)

1,339.40 554.65

Total Equity

4,629.74 2,698.62

Net Debt to Equity Ratio (Times)

0.29 0.21

As at March 31, 2023, the Companys total borrowings including lease liabilities amounted to ^1,154.51 Lakhs, while
cash and cash equivalents stood at Rs 1,505.71 Lakhs, resulting in a net negative debt position of Rs351.20 Lakhs.

Financial Risk Management Objectives and Policies

I. Financial Risk Management Framework

The Groups principal financial liabilities comprise trade payables and Other financial liabilities. The main purpose of
these financial liabilities is to finance the Groups operations. The Groups principal financial assets include Trade
receivables, loans, cash and bank balances and other financial assets.

The Group is exposed to market risk, credit risk and liquidity risk. The Board of Directors reviews policies for
managing each of these risks, which are summarised below:

1. Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from a change in
the price of a financial instrument. The value of a financial instrument may change as a result of changes in the
interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that
affect market risk sensitive instruments. Market risk is attributable to all market risk sensitive financial instruments
including investments and deposits, foreign currency receivables, payables and borrowing.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because
of changes in market interest rates. The Group has constantly monitoring mechanism for credit markets and
rebalances its financing strategies to achieve an optimal maturity profile and financing cost. Interest rate risk is
managed by the Group on an on-going basis with the primary objective of limiting the extent to which interest
expense could be affected by an adverse movement in interest rates. There are no hedging instruments to mitigate
this risk.

Foreign currency risk

Foreign currency risk is the risk that the fair value of future cash flows of a financial instruments will fluctuate
because of changes in foreign exchange rates. The Group is not exposed to material foreign exchange risk arising
from transactions i.e. imports of materials, recognised liabilities denominated in a currency that is not the Groups
functional currency. The Groups foreign currency risks are identified, measured and managed at periodic intervals
in accordance with the Groups policies.

2. Credit risk

Credit risk is the risk of financial loss to the Group if the customer or that counterparty to the financial instrument
fails to meet its contractual obligations and arises principally from the Groups receivables from customers, loans
and investments. Credit risk is managed through credit approvals, establishing credit limits and continuously
monitoring the credit worthiness of counterparty to which the Group grants credit terms in the normal course of
business.

Credit risk management

The finance function of the Group assesses and manages credit risk based on internal credit rating system. Internal
credit rating is performed for each class of financial instruments with different characteristics. The Group assesses
the credit risk for each class of financial assets based on the assumptions, inputs and factors specific to the class of
financial assets.

The risk parameters are same for all financial assets for all periods presented. The Group considers the probability
of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an on-
going basis throughout each reporting period. In general, it is presumed that credit risk has significantly increased
since initial recognition if the payments are more than 30 days past due . A default on a financial asset is when the
counterparty fails to make contractual payments when they fall due. This definition of default is determined by
considering the business environment in which entity operates and other macro-economic factors.

Trade Receivables: The Group has exposure to credit risk from trade receivables. The Group has used expected
credit loss (ECL) model for assessing the impairment loss. For the purpose, the Group uses a provision matrix to
compute the expected credit loss amount (if any). The provision matrix takes into account external and internal
risk factors and historical data of credit losses from various customers. The Group ensures that there is no
significant concentration of exposure to credit and therefore does not significantly impair the financial assets since
the customers are individuals from whom payment is received as the services are provided.

3. Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they become due. The
Group manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet
its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk
to the Groups reputation. Prudent liquidity risk management implies maintaining sufficient cash and marketable
securities and the availability of funding through an adequate amount of committed credit facilities to meet
obligations when due. Due to the nature of the business, the Group maintains flexibility in funding by maintaining
availability under committed facilities. The Groups treasury team is responsible for liquidity, funding as well as
settlement management. In addition, processes and policies related to such risks are overseen by senior

management. Management monitors the Groups liquidity position through rolling forecasts on the basis of
expected cash flows.

The following table details the remaining contractual maturities of the Groups financial liabilities at the end of the
reporting period, which are based on the contractual undiscounted cash flows and the earliest date the Group is
required to pay:

Particulars

Less than 1
year
1-2 year 2-3 year More than 3
years
Total

As at 31st March2025

Borrowings

1,720.71 22.34 24.50 125.89 1,893.44

Trade Payables

1,395.10 - - - 1,395.10

Lease Liabilities

17.92 21.28 19.25 109.01 167.46

Other Financial Liabilities

2.24 - - - 2.24

Other current liabilities

97.42 - - - 97.42

Total

3,233.40 43.62 43.75 234.90 3,555.67

 

Particulars

Less than 1
year
1-2 year 2-3 year More than 3
years
Total

As at 31st March 2024

Borrowings

1,379.89 19.90 21.87 150.85 1,572.52

Trade Payables

76.75 - - - 76.75

Lease Liabilities

10.84 13.19 15.82 127.78 167.63

Other Financial Liabilities

1.54 - - - 1.54

Other current liabilities

90.05 - - - 90.05

Total

1,559.07 33.09 37.69 278.63 1,908.49

 

Particulars

Less than 1
year
1-2 year 2-3 year More than 3
years
Total

As at 31st March 2023

Borrowings

767.40 18.10 19.90 172.73 978.12

Trade Payables

103.47 - - - 103.47

Lease Liabilities

8.76 10.84 13.19 143.60 176.39

Other Financial Liabilities

0.80 - - - 0.80

Other current liabilities

73.49 - - - 73.49

Total

953.91 28.94 33.09 316.33 1,332.27

II. Financial instruments by category

For amortised cost instruments, carrying value represents the best estimate of fair value.

As at

31st March2025

Particulars

FVTPL FVOCI Amortised Cost

Financial assets

Investment

-

- 500.00

Trade receivables

-

-

3,286.72

Loans

-

-

-

Cash and cash equivalents

-

-

721.50

Other Financial Assets

-

-

276.88

Total

-

-

4,785.11

Financial liabilities

As at

31st March2025

Particulars

FVTPL FVOCI Amortised Cost

Borrowings

- - 1,893.44

Trade payables

- - 1,395.10

Lease Liabilities

- - 167.46

Other Financial Liabilities

- - 2.24

Total

- - 3,458

 

As at

Particulars

31st March 2024

FVTPL FVOCI Amortised Cost

Financial assets

Investment

- - -

Trade receivables

- - 1,359.22

Loans

- - 7.83

Cash and cash equivalents

- - 1,185.50

Other Bank Balance

- - -

Other Financial Assets

- - 151.70

Total

- - 2,704.25

Financial liabilities

Borrowings

- - 1,572.52

Trade payables

- - 76.75

Lease Liabilities

- - 167.63

Other Financial Liabilities

- - 1.54

Total

- - 1,818.44

 

Particulars

As at 31st March 2023

FVTPL FVOCI Amortised Cost

Financial assets

Investment

- - 0.10

Trade receivables

- - 90.84

Loans

- - 5.21

Cash and cash equivalents

- - 1,505.71

Other Financial Assets

- - 50.80

Total

- - 1,652.66

Financial liabilities

Borrowings

- - 978.12

Trade payables

- - 103.47

Lease Liabilities

- - 176.39

Other Financial Liabilities

- - 0.80

Total

- - 1,258.78

Fair value measurements
I. Financial instruments by category

Financial assets and financial liabilities measured at fair value in the financial statement are grouped into three
Levels of a fair value hierarchy. The three Levels are defined based on the observability of significant inputs to
the measurement, as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either
directly (prices) or indirectly (derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data.

II. Assets and Liabilities which are measured at Amortised Cost for which Fair Values are Disclosed

As at 31st March2025

Level 1 Level 2 Level 3 Total

Financial Assets

Investment

- - 500.00 500.00

Trade receivables

- 3,286.72 - 3,286.72

Loans

- - - -

Cash and cash equivalents

- 721.50 - 721.50

Other Financial Assets

- 276.88 - 276.88

Total Financial Assets

- 4,285.11 500.00 4,785.11

Financial Liabilities

Borrowings

- 1,893.44 - 1,893.44

Trade payables

- 1,395.10 - 1,395.10

Lease Liabilities

- 167.46 - 167.46

Other Financial Liabilities

- 2.24 - 2.24

Total Financial Liabilities

- 3,458.24 - 3,458.24

 

As at 31st March 2024

Level 1 Level 2 Level 3 Total

Financial Assets

Investment

- - - -

Trade receivables

- 1,359.22 - 1,359.22

Loans

- 7.83 - 7.83

Cash and cash equivalents

- 1,185.50 - 1,185.50

Other Financial Assets

151.70 - 151.70

Total Financial Assets

- 2,704.25 - 2,704.25

Financial Liabilities

Borrowings

- 1,572.52 - 1,572.52

Trade payables

- 76.75 - 76.75

Lease Liabilities

- 167.63 - 167.63

Other Financial Liabilities

- 1.54 - 1.54

Total Financial Liabilities

- 1,818.44 - 1,818.44

 

As at 31st March 2023

Level 1 Level 2 Level 3 Total

Financial Assets

Investment

- - 0.10 0.10

Trade receivables

- 90.84 - 90.84

Loans

- 5.21 - 5.21

Cash and cash equivalents

- 1,505.71 - 1,505.71

Other Financial Assets

- 50.80 - 50.80

Total Financial Assets

- 1,652.56 0.10 1,652.66

Financial Liabilities

Borrowings

- 978.12 - 978.12

Trade payables

- 103.47 - 103.47

Lease Liabilities

- 176.39 - 176.39

Other Financial Liabilities

- 0.80 - 0.80

Total Financial Liabilities

- 1,258.78 - 1,258.78

Valuation Process and Technique Used to Determine Fair Value

Specific valuation techniques used to value financial instruments include:

(a) The use of quoted market prices or dealer quotes for similar instruments

(b) The fair value of the remaining financial instruments is determined based on the following methods:

i. Net assets value method

ii. Valuation of investment in unquoted equity shares has been made using the Discounted cash-flow method and
Net assets value method, as deemed fit by the Grous management.

Risk adjustments specific to the counterparties (including assumptions about credit default rates) are derived from
credit risk grading determined by the Groups internal credit risk management group.

Business Combination - Acquisitions during the year ended March 31, 2023

Acquisition of identified assets and liabilities of M/s.Gaudium Bawa IVF

During the year 2022-23, the Company had acquired specifically identified assets and liabilities of M/s. Gaudium
Bawa IVF partnership firm.The excess of the purchase consideration over the value of specifically identified assets
and liabilities resulted in a goodwill of ? 13.08 Lakhs for the Company, which comprises the value of expected
synergies arising from the acquisition. The entire amount of goodwill is considered to be associated with one of the
IVF Centres ("Cash Generating Unit", "CGU"), which is part of the business of the Company.

Goodwill Impairment

The Company performed its impairment test for period ended 31st March 2025. The Company considers the
relationship between recoverable value of net assets taken over and its carrying value, among other factors, when
reviewing for indicators of impairment. As at 31st March 2025, the recoverable value of the net assets taken over was
higher than the carrying value and no other indicators of impairment were identified. Therefore, no impairment loss
allowance is provided for the period ended 31st March 2025.

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.